Halozyme director sells 5,230 shares of Halozyme stock

Published on 10/06/2026 at 15:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 481.00 million in the second quarter, up 47.70 percent. Halozyme stock costs EUR 96.90 on October 6, 2026 after EUR 97.39.

HALO, US40637H1095, Illustration mit AI erstellt.

Halozyme Therapeutics (US40637H1095) was trading at EUR 96.90 at Lang & Schwarz on October 6, 2026 at 3:31 p.m. CEST, down 0.50 percent versus the EUR 97.39 prior close. The latest corporate transaction involved director Matthew Posard, who sold 5,230 shares on October 1, 2026, according to MarketBeat.

Insider sale meets strong results

Posard sold the shares at an average price of USD 108.54 for total proceeds of USD 567,664.20. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, and his remaining direct ownership stood at 53,609 shares, MarketBeat reported on October 2, 2026.

The sale arrives after a strong second quarter. Revenue was USD 481.00 million, compared with USD 402.28 million expected, while reported earnings per share reached USD 2.28 against a USD 1.79 consensus estimate, according to MarketBeat on September 30, 2026.

Guidance keeps the numbers elevated

Revenue increased 47.70 percent year over year in the second quarter, and Halozyme set fiscal 2026 earnings-per-share guidance at USD 8.65-9.00. The company also reported USD 481.00 million of quarterly revenue against the USD 402.28 million consensus, a USD 78.72 million difference that puts the guidance range in the context of a substantial quarterly estimate beat.

MarketBeat listed nine buy ratings, three holds and one sell among 13 analysts on September 30, 2026. The consensus rating was Moderate Buy, but the average 12-month target of USD 91.20 sat below the USD 109.43 Nasdaq quote available on October 6, 2026, making the analyst average a counterweight to the operating momentum.

Nasdaq quote remains below yearly high

The primary Nasdaq quote was USD 109.43 at 9:33 a.m. EDT on October 6, 2026, with a 52-week range of USD 61.23 to USD 116.85. That places the primary-market quote USD 7.42, or 6.35 percent, below the yearly high, while the separate euro quotation at Lang & Schwarz was EUR 96.90 at 3:31 p.m. CEST, down 0.50 percent from the EUR 97.39 prior close.